ANBITION’s pipeline also includes the development of selective delivery systems to improve the therapeutic index of drugs for oncology applications.
Such delivery systems are based on human albumin nanoparticle carriers (NP-HSA) loaded with drugs and decorated with targeting agents like antibody fragments and bioactive peptides.